Gender-affirming hormone therapy may reduce the risk of prostate cancer in transgender women, but it may also increase the risk of biochemical recurrence and bone metastases in patients with prostate ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD. Radium-223 provided a 3-month improvement in radiographic ...

Theriva™ (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with ...

How Breast Cancer Cells Survive in Bone Marrow After Remission ... regardless of the type of treatment ... Scientists Discover That Special Immune Cells Stop Metastatic Cancer Oct. 7, 2024 ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

The NHS England is rolling out new treatments for patients who suffer from rare cancer. Tebentafusp, is a new drug approved ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to a prostate cancer ...

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...

A Cork University Hospital trial of physical therapy for men battling metastatic cancers of the urinary tract and reproductive systems – and named with a nod to a hurling legend – is already ...